FFTY vs. BIS
FFTY (Innovator IBD 50 ETF) and BIS (ProShares UltraShort Nasdaq Biotechnology) are both exchange-traded funds - FFTY is a Large Cap Growth Equities fund tracking the IBD 50 Index, while BIS is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (-200%). Both are passively managed. Over the past 10 years, FFTY returned 7.57%/yr vs -23.34%/yr for BIS. At a correlation of -0.59, they often move in opposite directions. FFTY charges 0.80%/yr vs 0.95%/yr for BIS.
Performance
FFTY vs. BIS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FFTY achieves a 20.11% return, which is significantly higher than BIS's -6.36% return. Over the past 10 years, FFTY has outperformed BIS with an annualized return of 7.57%, while BIS has yielded a comparatively lower -23.34% annualized return.
FFTY
- 1D
- -0.14%
- 1M
- 7.67%
- YTD
- 20.11%
- 6M
- 21.02%
- 1Y
- 38.14%
- 3Y*
- 21.57%
- 5Y*
- -0.60%
- 10Y*
- 7.57%
BIS
- 1D
- -3.65%
- 1M
- 2.35%
- YTD
- -6.36%
- 6M
- -4.11%
- 1Y
- -49.58%
- 3Y*
- -21.43%
- 5Y*
- -14.49%
- 10Y*
- -23.34%
FFTY vs. BIS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
FFTY Innovator IBD 50 ETF | 20.11% | 23.38% | 18.36% | 12.40% | -51.08% | 11.92% | 18.20% | 25.74% | -16.76% | 37.62% |
BIS ProShares UltraShort Nasdaq Biotechnology | -6.36% | -45.95% | 4.79% | -6.54% | -2.14% | -14.74% | -56.01% | -41.01% | 5.14% | -36.98% |
Correlation
The correlation between FFTY and BIS is -0.43, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.43 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.49 |
Correlation (5Y) Calculated over the trailing 5-year period | -0.54 |
Correlation (10Y) Calculated over the trailing 10-year period | -0.59 |
Correlation (All Time) Calculated using the full available price history since Apr 10, 2015 | -0.59 |
The correlation between FFTY and BIS shifts across timeframes, from -0.59 (all time) to -0.43 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FFTY vs. BIS — Risk / Return Rank
FFTY
BIS
FFTY vs. BIS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Innovator IBD 50 ETF (FFTY) and ProShares UltraShort Nasdaq Biotechnology (BIS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| FFTY | BIS | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.12 | -1.25 | +2.38 |
Sortino ratioReturn per unit of downside risk | 1.55 | -1.99 | +3.54 |
Omega ratioGain probability vs. loss probability | 1.20 | 0.78 | +0.42 |
Calmar ratioReturn relative to maximum drawdown | 1.65 | -0.91 | +2.56 |
Martin ratioReturn relative to average drawdown | 4.36 | -1.25 | +5.61 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| FFTY | BIS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.12 | -1.25 | +2.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.02 | -0.33 | +0.31 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.28 | -0.50 | +0.78 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.20 | -0.67 | +0.87 |
Drawdowns
FFTY vs. BIS - Drawdown Comparison
The maximum FFTY drawdown since its inception was -59.46%, smaller than the maximum BIS drawdown of -99.87%. Use the drawdown chart below to compare losses from any high point for FFTY and BIS.
Loading charts...
Drawdown Indicators
| FFTY | BIS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.46% | -99.87% | +40.41% |
Max Drawdown (1Y)Largest decline over 1 year | -23.29% | -54.50% | +31.21% |
Max Drawdown (3Y)Largest decline over 3 years | -29.60% | -66.87% | +37.27% |
Max Drawdown (5Y)Largest decline over 5 years | -59.46% | -74.80% | +15.34% |
Max Drawdown (10Y)Largest decline over 10 years | -59.46% | -95.25% | +35.79% |
Current DrawdownCurrent decline from peak | -15.34% | -99.85% | +84.51% |
Average DrawdownAverage peak-to-trough decline | -22.38% | -90.03% | +67.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.77% | 39.59% | -30.82% |
Volatility
FFTY vs. BIS - Volatility Comparison
The current volatility for Innovator IBD 50 ETF (FFTY) is 9.42%, while ProShares UltraShort Nasdaq Biotechnology (BIS) has a volatility of 13.87%. This indicates that FFTY experiences smaller price fluctuations and is considered to be less risky than BIS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FFTY | BIS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.42% | 13.87% | -4.45% |
Volatility (6M)Calculated over the trailing 6-month period | 26.18% | 30.95% | -4.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 34.09% | 39.68% | -5.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 29.14% | 43.74% | -14.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.41% | 46.36% | -18.95% |
FFTY vs. BIS - Expense Ratio Comparison
FFTY has a 0.80% expense ratio, which is lower than BIS's 0.95% expense ratio.
Dividends
FFTY vs. BIS - Dividend Comparison
FFTY's dividend yield for the trailing twelve months is around 1.12%, less than BIS's 4.92% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
BIS ProShares UltraShort Nasdaq Biotechnology | 4.92% | 5.25% | 3.73% | 1.75% | 0.00% | 0.00% | 0.45% | 2.11% | 0.37% | 0.00% |
FFTY Innovator IBD 50 ETF | 1.12% | 1.35% | 0.91% | 0.65% | 2.75% | 0.22% | 0.00% | 0.00% | 0.00% | 0.17% |
Frequently Asked Questions
FFTY and BIS have a correlation of -0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIS has higher volatility (13.87%) compared to FFTY (9.42%). In terms of maximum drawdown, FFTY dropped -59.46% vs BIS's -99.87%.
On 10-year performance, FFTY leads with 7.57% vs -23.34% for BIS. On fees, FFTY is cheaper at 0.80% per year. On volatility, FFTY has been the lower-risk option at 9.42%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, FFTY has performed better with a 7.57% return vs -23.34%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
FFTY is cheaper with a 0.80% expense ratio, compared with 0.95% for BIS.
BIS has the higher dividend yield at 4.92%, compared with 1.12% for FFTY.
FFTY is categorized as Large Cap Growth Equities, while BIS is Leveraged Equities. FFTY tracks IBD 50 Index, while BIS tracks NASDAQ Biotechnology Index (-200%). They also come from different issuers: Innovator and ProShares. Their fees differ too: 0.80% for FFTY and 0.95% for BIS.
FFTY currently has the higher Sharpe Ratio (1.12 vs -1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FFTY and BIS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer